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ABSTRACT
Pulmonary hypertension was defined as mean pulmonary artery pressure25 mmHg at the 4th World Sympo-
sium on Pulmonary Hypertension. In 2009, the European Society of Cardiology and European Respiratory So-
ciety jointly created guidelines for practical pulmonary hypertension classifications and treatments based on the
discussions at the 4th World Symposium. This classification is characterized by division into five groups: Pul-
monary arterial hypertension (PAH); Pulmonary hypertension due to left heart disease; Pulmonary hyperten-
sion due to lung disease andor hypoxia; Chronic thromboembolic pulmonary hypertension; and Pulmonary hy-
pertension with unclear andor multifactorial mechanisms.
PAH is a common and fatal complication of connective tissue disease (CTD), but pulmonary hypertension in
CTD consists of PAH, pulmonary hypertension caused by myocardial involvement, pulmonary veno-occlusive
disorder, pulmonary hypertension due to interstitial lung disease. PAH has been studied widely in SSc and the
estimated prevalence of 7-12%. Treatment of CTD associated PAH (CTD-PAH) consists of general therapeutic
options and specific treatment. Specific treatment of CTD-PAH patients is targeted to produce vasodilatation.
Calcium channel blockers (CCBs) are indicated in cases where a sufficient decrease in pulmonary arterial pres-
sure is seen in vasoreactivity testing. If vasoreactivity is absent in CTD-PAH patients, the treatment consists of
the endothelin receptor antagonists, the prostacyclin analogues and phosphodiesterase-type 5 inhibitors. Few
data are available to support the use of immunosuppression in CTD-PAH. However, some case reports sug-
gested that a minority of CTD-PAH patients could benefit from immunosuppressive therapy. The treatment of
CTD-PAH patients may differ from the treatment of idiopathic PAH.
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INTRODUCTION
Pulmonary hypertension (PH) was defined as mean
pulmonary artery pressure (PAPm)25 mmHg at the
4th World Symposium on Pulmonary Hypertension
held at Dana Point in the United States in 2008. De-
finitive diagnosis of this condition thus requires di-
rect measurement of pulmonary arterial pressure us-
ing right heart catheterization (RHC).1 However, esti-
mation of the existence of PH from the shape of the
left and right ventricles on echocardiography has be-
come relatively easy in recent years. With the concur-
rent use of Doppler echocardiography, it is even pos-
sible to estimate systolic pulmonary arterial pressure
and cardiac output values. These pulmonary hemody-
namic parameters are measured in various diseases,
leading to the discovery that PH complications occur
at a higher rate in many diseases than was previously
thought. At the 4th World Symposium on PH, there-
fore, a clinical classification of PH (Dana Point classi-
fication) was created that grouped PH with many
common conditions and treatments.1 In 2009, the
European Society of Cardiology (ESC) and European
Respiratory Society (ERS) jointly created guidelines
for more practical PH classifications and treatments
based on the discussions at the 4th World Sympo-
Allergology International. 2011;60:419-424
REVIEW ARTICLE
1Division of Pulmonary Circulation, Department of Cardiovascular
Medicine, National Cerebral and Cardiovascular Center, Osaka,
Japan.
Correspondence: Norifumi Nakanishi, MD, PhD, Division of Pul-
monary Circulation, Department of Cardiovascular Medicine, Na-
tional Cerebral and Cardiovascular Center, 5−7−1 Fujishiro-dai,
Suita, Osaka 565−8565, Japan.
Email: nnakanis@hsp.ncvc.go.jp
Received 16 August 2011.
2011 Japanese Society of Allergology
DOI: 10.2332allergolint.11-RAI-0362
Nakanishi N
420 Allergology International Vol 60, No4, 2011 www.jsaweb.jp
Table　1　Updated clinical classifi cation of pulmonary hyper-
tension
1. Pulmonary Arterial Hypertension: PAH
1.1 Idiopathic PAH
1.2 Heritable
1.2.1 BMPR2
1.2.2 ALK1, endoglin (with or without hereditary hemor-
rhagic telangiectasia)
1.2.3 Unknown
1.3 Drug- and toxin-induced
1.4 Associated with
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.4.6 Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn
1’. Pulmonary Veno-Occlusive Disease (PVOD) and/or Pul-
monary capillary hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
3. Pulmonary hypertension owing to lung disease and/or hy-
poxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and 
obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to hight altitude
3.7 Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mecha-
nisms
5.1 Hematologic disorders: myeloproliferative disorders,
splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langer-
thans cell histiocytosis: lymphangioleiomyomatosis,
neurofi bromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gau-
cher disease, thyroid disorders
5.4 Others: tumoral obstruction, fi brosing mediastinitis,
chronic renal failure on dialysis
Adapted from reference 1.
sium on PH.2 The present article first reviews the
ESCERS clinical classification of PH, diagnostic al-
gorithms, and evidence-based treatment algorithms,
and then explains the characteristics of PH associ-
ated with connective tissue disease.
ESCERS CLINICAL CLASSIFICATION OF
PH
The ESCERS clinical classification of PH adopts the
same classification method as the Dana Point classifi-
cation.1 This classification is characterized by division
into five groups: Group 1, Pulmonary arterial hyper-
tension (PAH); Group 2, Pulmonary hypertension
due to left heart disease; Group 3, Pulmonary hyper-
tension due to lung disease andor hypoxia; Group 4,
Chronic thromboembolic pulmonary hypertension
(CTEPH); and Group 5, Pulmonary hypertension
with unclear andor multifactorial mechanisms (Ta-
ble 1).
GROUP 1: PAH
Since the first clinical classification of PH was estab-
lished in 1998,3 PAH has been placed at the most im-
portant and typical disorder of PH. In the Dana Point
classification, PAH is subdivided into: idiopathic
PAH; heritable PAH; drug- and toxin-induced PAH;
PAH associated with other disorders; and persistent
PH of the newborn. In Group 1’, the subtypes of pul-
monary veno-occlusive disease (PVOD) and pulmo-
nary capillary hemangiomatosis (PCH) were estab-
lished. The conditions listed as “associated with other
disorders” - connective tissue disease, HIV infection,
portal hypertension, congenital heart disease, schis-
tosomiasis, and chronic hemolytic anemia - are taken
as diseases that can cause PAH.
IDIOPATHICHERITABLE PAH
PAH is the generic term for diseases in which serious
lesions exist in the pulmonary artery itself, and PH
occurs with a high frequency as a result.4 Among
PAH, cases in which no obvious primary disease can
be identified are categorized as “idiopathic PAH.5” In
2000, BMPR2 germline mutations, which are be-
lieved to be associated with the onset of PAH, were
discovered in PAH patients with a family history of
the condition.6 In 2001, patients were also found to
have a mutation in a gene called ACVRL1 (ALK1).7
As a result, PAH cases in which the patient has a con-
firmed gene mutation were defined together with
conventional familial PAH cases (regardless of
whether a gene mutation is confirmed) as “heritable
PAH.”
CONNECTIVE TISSUE DISEASE-ASSOCIA-
TED PAH (CTD-PAH)
In the previous classification, this was called “PAH re-
lated to collagen vascular disease,” but was changed
to CTD-PAH in the Dana Point classification.5 Many
cases of CTD-PAH have been described and this is a
clinically important subgroup. Investigations of PAH
in systemic sclerosis (SSc) are ongoing in Western
countries, and the complication rate of PAH in SSc is
reported to be 7-12%.8,9 The prognosis of SSc with
concomitant PH is poor compared with idiopathic
PAH.10 The PAH complication rate in systemic lupus
erythematosus (SLE) and mixed connective tissue
disease (MCTD) is unknown, but the frequency is re-
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ported to be lower than with SSc. In Japan, however,
the PH complication rates in MCTD and SLE are
high, reportedly reaching 16% in MCTD, 9.3% in SLE,
and 11.4% in SSc.
PORTOPULMONARYHYPERTENSION(POPH)
Some 2-6% of Portal hypertension cases are said to
have PH, representing POPH.11 Much is unknown
about the mechanisms of onset for POPH, and the ex-
istence of portal hypertension itself is thought to be a
determinant in the development of PH.12 PH exists in
the initial stage of POPH, but causes include high
cardiac output or diastolic dysfunction of left ventricle
in many cases the calculated pulmonary vascular re-
sistance is normal. When the terminal stage of the
disease is reached, however, the pulmonary hemody-
namics in this condition are the same as in idiopathic
PAH. The pathological findings in POPH and idi-
opathic PAH are also very similar.13
CONGENITAL HEART DISEASE-ASSOCIA-
TED PAH (CHD-PAH)
CHD-PAH has long been an important subgroup of
PAH. In congenital heart disease, pulmonary blood
flow increases as a result of systemic-to-pulmonary
shunt, resulting in PH. This occasions organic
changes in pulmonary vessels, and PAH is reported
to occur with a high frequency. In reports from
Europe and North America, the frequency of PAH as-
sociated with congenital systemic to pulmonary shunt
is 1.6-12.5 per 1 million adults, with Eisenmenger
changes estimated to occur in 25-50% of these.14
PULMONARY VENO-OCCLUSIVE DISEASE
(PVOD) ANDOR PULMONARY CAPILLARY
HEMANGIOMATOSIS (PCH)
Both of these diseases have much in common with
PAH, and PVOD and PCH together are categorized
as a subgroup of Group 1 in the Dana Point classifica-
tion. Similarities also exist in the histological presen-
tations of PCH and PVOD.15 However, PAH and
PVODPCH differ greatly in responsiveness to medi-
cal treatment. A particularly striking difference is that
pulmonary edema occurs in about half of patients in
response to PAH therapeutic agents. The prognosis
is also poorer than for PAH. There is also some de-
bate about classifying PVODPCH in PAH.
Other diseases classified in PAH, including drug-
and toxin-induced PAH, HIV infection, schistosomia-
sis, and chronic hemolytic anemia, occur in few cases
in Japan and are not discussed here.
GROUP 2: PH DUE TO LEFT HEART DIS-
EASE
Left heart disease may be the most common cause of
PH. PH in this group is subtyped into PH secondary
to systolic dysfunction, diastolic dysfunction, and val-
vular disease. It is reported that 60-70% of patients
with left ventricular dysfunction may present with
PH.16 However, in PH due to left heart disease, pul-
monary arterial pressure is elevated, but pulmonary
wedge pressure is also high. As a result, calculated
pulmonary vascular resistance is not increased in
many cases.
GROUP 3: PH DUE TO LUNG DISEASE
ANDOR HYPOXIA
Group 3 consists of PH associated with hypoxemia
and various respiratory diseases, including chronic
obstructive pulmonary disease, interstitial lung dis-
ease, sleep-disordered breathing, or chronic expo-
sure to high altitude. In cases due to interstitial lung
disease, the PH is not generally conspicuous, and the
percentage of patients showing high-level PH with
PAPm 40 mmHg is reportedly around 1%.17 At the
4th World Symposium on PH, new PH accompanying
other pulmonary diseases with mixed restrictive and
obstructive patterns was adopted as a condition differ-
ent from PH accompanying other respiratory disease.
This disease is a specific disease group in that many
cases present with a higher level of PH than expected
from the severity of the respiratory dysfunction.18
GROUP 4: CHRONIC THROMBOEMBOLIC
PULMONARY HYPERTENSION (CTEPH)
Group 4 is PH caused by organizing thrombus pre-
sent in the pulmonary artery.19 Many of these pa-
tients have a history of acute pulmonary thromboem-
bolism. CTEPH was previously subtyped into central
and peripheral types, depending on the location of
the main occlusion. However, many cases are seen in
which even specialists have differing opinions when
distinguishing between the central and peripheral
types.
GROUP 5: PH WITH UNCLEAR MULTIFAC-
TORIAL MECHANISMS
In recent years, the diseases occurring concurrently
with PH have been shown to be more diverse than
was previously known. In the Dana Point classifica-
tion, diseases that have been found in recent years to
occur concurrently with PH are placed into four sub-
groups: hematological disorders; systemic disorders;
metabolic disorders; and others. These diseases are
particularly rare cases even among PH, which is itself
already rare. However, findings from diseases in such
cases may provide clues for a better understanding of
the onset of PH, and elucidation of the causes of
these diseases is desired.
DIAGNOSTIC ALGORITHM OF DISEASES
THAT ARE CARDINAL SIGNS OF PH
Currently, semiquantitative evaluation of pulmonary
arterial hemodynamic parameters using Doppler
echocardiography is possible in addition to chest ra-
diography and electrocardiography. This has made it
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much easier than before to infer the existence of PH.
In cases when PH is suspected based on noninvasive
diagnostic methods, generally a definitive diagnosis
of PH is first made, followed by a differential diagno-
sis of the type of PH. The severity of each case is
then assessed. In definitive diagnosis of PH, measure-
ment of pulmonary hemodynamic parameters using
RHC is ultimately required, as mentioned above.
When conducting a differential diagnosis of each
type of PH, diagnosis of Group 3 (PH due to lung dis-
ease) is first done based on chest radiography and
pulmonary function tests. It is also possible to simul-
taneously diagnose Group 2 (PH due to left heart dis-
ease) using Doppler echocardiography. If Group 2
and Group 3 PH can be excluded, the likelihood is
high that remaining cases of PH will belong to Group
1 (PAH) or Group 4 (CTEPH). In distinguishing be-
tween these two, ventilationperfusion lung scan is
the essential test.20 Nearly all cases that show normal
or mottled pattern findings on perfusion lung scan
can be placed in Group 1 (PAH). If multiple wedge-
shaped perfusion defects are present on ventilation
perfusion lung scan, the possibility of Group 4
(CTEPH) is high. Group 5 diseases are particularly
rare among PH, so this may be offered as a differen-
tial diagnosis after other forms of PH have been ade-
quately excluded.
In cases when Group 1 (PAH) is diagnosed from a
ventilationperfusion lung scan, it is next necessary
to distinguish between idiopathicheritable PAH and
other forms of PAH. Very few reports have described
PAH due to drug- and toxin-induced PAH, HIV infec-
tion, schistosomiasis, and chronic hemolytic anemia
in Japan, and these types can be excluded relatively
easily with sufficient history taking. With CTD-PAH,
POPH, and CHD-PAH, the presence of connective tis-
sue disease, liver disease, and congenital heart dis-
ease, respectively, is diagnosed, and diagnosis is not
difficult with the subsequent occurrence of PH. Cases
in which these forms of PAH are excluded and the re-
maining underlying disease cannot be identified are
idiopathicheritable PAH and PVODPCH. Heritable
PAH, newly established in the Dana Point classifica-
tion, is defined for cases in which a family history or
gene mutation is confirmed. However, considering
the ethical problems of performing genetic tests and
that only one or two institutions in Japan can perform
genetic tests for this condition, determination of heri-
table PAH is difficult in general clinical settings. The
difference between regular PAH and PVODPCH
stems from the difference in whether the site of the
main lesion in the pulmonary vessels is the pulmo-
nary artery or pulmonary veins or capillaries. Diagno-
sis is considered to be possible from image findings
such as chest radiography or computed tomography
(CT), and responsiveness to PH therapeutic agents.
However, many cases do not show differences in
clinical features, and distinguishing between the two
is often difficult even in specialty institutions.
Most cases in which multiple wedge-shaped perfu-
sion defects can be confirmed on perfusion lung scan
may be considered to belong in Group 4 (CTEPH).
However, lesions also exist in the pulmonary artery in
some aortitis syndrome patients, and multiple wedge-
shaped perfusion defects are seen on perfusion lung
scans even in rare diseases such as primary or secon-
dary tumor in the pulmonary artery. In aortitis syn-
drome, diagnosis is possible from various clinical
symptoms originating in vascular lesions of the aorta.
In CTEPH, tests including CT, magnetic resonance
imaging, and RHCpulmonary arteriography are sub-
sequently conducted, the severity of the condition is
evaluated, and surgical indications are investigated.
TREATMENT FOR PH
The evidence-based treatment algorithm modified by
the ESCERS from the Dana Point Treatment Algo-
rithm is shown as follows2(Fig. 1). In the clinical tri-
als that have provided accepted evidence for many
commercially available PH therapeutic agents, sub-
jects were limited to patients with idiopathicherita-
ble PAH and CTD-PAH, and a small number with
CHD-PAH. Drugs currently available to treat Group 2
(PH due to left heart disease), Group 3 (PH due to
lung disease), and CTEPH are thus not formally indi-
cated, and treatment effects have not been sufficiently
substantiated.
In the ESCERS Evidence-Based Treatment Algo-
rithm, first a definitive diagnosis of PAH is made and
its severity is evaluated, then right heart failure is
treated using oral anticoagulants, diuretics, or di-
goxin, and O2 or other supportive therapy is given.
Next, vasoreactivity testing is recommended. Cal-
cium channel blockers (CCBs) are indicated in cases
where a sufficient decrease in pulmonary arterial
pressure is seen in vasoreactivity testing.21,22 If WHO
functional class I-II can be maintained with CCB, this
treatment is continued. In patients without vascular
reactivity, specific drug therapy for PAH is started. In
the ESCERS Evidence-Based Treatment Algorithm,
the WHO functional class severity is emphasized
when selecting a PH therapeutic agent. If the WHO
functional class is II or III, endothelin receptor an-
tagonists or phosphodiesterase type-5 inhibitors are
selected.23-26 In Japan, Beraprost, an orally active
prostacyclin analogue, is included among the op-
tions.27 However, there is very little evidence to refer
to in deciding which of the three types of drug to use.
Continuous intravenous administration of epopros-
tenol is the first choice even with WHO functional
class III or class IV.28 In cases when necessary im-
provements in symptoms are not obtained with
monotherapy, concurrent therapy with two or three
additional drugs is given. When the concurrent ther-
apy is with oral drugs only, the oral drugs and epo-
prostenol are used in combination. However, data are
PH Guidelines and Connective Tissue Disease
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Fig.　1　Evidence-based treatment algorithm for pulmonary arterial hypertension patients (for group 1 patients only). †To 
maintain arterial blood O2 pressure ≥8 kPa (60 mmHg). ‡Under regulatory review in the European Union. §Ila-C for 
WHO-FC IL. APAH, associated pulmonary arterial hypertension; BAS, balloon atrial septostomy; CCB, calcium channel 
blocker; ERA, endothelin receptor antagonist; IPAH, idiopathic pulmonary arterial hypertension; PDE5 I; phosphodiester-
ase type-5 inhibitor; WHO-FC, World Health Organization functional class. Adapted from reference 2.
Expert Referral (I-C)
VASOREACTIVE
WHO-FCI-III
CCB (I-C)
YES
Continue CCB
NO
Sustained response
(WHO-FCI-II)
NON VASOREACTIVE
INITIAL THERAPY
Recommendation-
Evidence WHO-FC II
Ambrisentan, Bosentan,
Sildenafil
Tadalafil‡
Sitaxentan Iloprost i.v., Treprostinil i.v. Ambrisentan, Bosentan,
Sitaxentan, Sildenafil,
Tadalafil‡,
Iloprost inhaled, and i.v.
Treprostinil s.c., i.v., inhaled‡
Initial Combination Therapy
Beraprost
INADEQUATE CLINICAL RESPONSE
INADEQUATE CLINICAL RESPONSE
BAS (I-C) and/or
Lung transplantation (I-C)
Sequential combination therapy (IIa-B)§
+ +
+Prostanoids PDE-5 I
Tadalafil‡
Treprostinil s.c., inhaled‡
Ambrisentan, Bosentan,
Sitaxentan,
Sildenafil
Epoprostenol i.v., Iloprost inhaled
Epoprostenol i.v.
WHO-FC III WHO-FC IV
I-A
I-B
IIa-C
IIb-B
Acute vasoreactivity test
(I-C for IPAH) (IIb-C for APAH)
Avoid pregnancy (I-C)
Influenza and pneumococcal
immunization (I-C)
Supervised rehabilitation (IIa-B)
Psycho-social support (IIa-C)
Avoid excessive physical activity (III-c)
General measures and supportive therapy Diuretics (I-C)
Oxygen† (I-C)
Oral anticoagulants:
IPAH, heritable PAH and PAH
due to anorexigens (IIa-C)
APAH (IIb-C)
Digoxin (IIb-C)
ERA
currently lacking for judging the relative merits for
ways of combining the three types of drugs. In cases
where resistance to medical therapy is shown or
when medical therapy cannot be given, lung trans-
plantation must also be considered.
The preceding describes the ESCERS Guidelines
for the diagnosis and treatment of PH, which will
probably become the main guidelines in the coming
years. However, no consensus of opinion has been
reached regarding which drugs are appropriate to
use for which conditions, and unfortunately there is
no discussion of this in the Guidelines.
CHARACTERISTICS OF PH IN CONNEC-
TIVE TISSUE DISEASE
PH complications are one major factor that deter-
mines the prognosis of connective tissue disease, and
appropriate PAH therapies are needed to improve the
prognosis for this condition. Normally, when PH is
secondary to connective tissue disease, the condition
is thought to be CTD-PAH due to an unambiguous
pulmonary vessel lesion. However, the etiology of PH
seen in connective tissue disease involves other fac-
tors to various extents, including cases in which a
thrombus exists in the pulmonary artery, cases
where vasculitis is closely involved, cases where pul-
monary fibrosis complicates connective tissue dis-
ease and results in hypoxemia as the main condi-
tions, and cases where myocardial damage and left
ventricular diastolic dysfunction secondary to connec-
tive tissue disease are involved. Therefore, adequate
evaluation of the level of contribution of each of these
factors is thus necessary when thinking about treat-
ment for this condition. In CTD-PAH, immune abnor-
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malities contribute to the onset, and cases have been
reported in which PH improves with steroids or im-
munosuppressants.29 This point is vastly different
from other PAH treatments that use only therapeutic
agents specialized for PAH in three types: the prosta-
cyclin pathway; endothelin pathway; and nitric oxide
pathway. Currently, trials that gather evidence with
consideration of the above conditions have finally
started for the treatment of PAH seen in connective
tissue disease. In summary, the treatment of CTD-
PAH patients may differ from the treatment of idi-
opathic PAH.
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